Chronic obstructive pulmonary disease (COPD) is characterized by irreversible deterioration of the airway wall. Cigarette smoking is the major trigger, and in vitro studies showed that cigarette smoke extract (CSE) induced mitophagy in airway epithelial cells via oxidative stress, but this mechanism was not studied in airway smooth muscle cells (ASMCs). Primary ASMCs isolated from COPD patients or non-disease donors were investigated for CSE-induced remodeling and mitochondria structure. Proteins were assessed by Western blots for remodeling: collagen type-I, α-smooth muscle actin (α-SMA) and fibronectin; autophagy: beclin-1, protein62 (p62), light chain (LC)3A/B; mitochondria activity: mitochondrially encoded cytochrome c oxidase II & -IV (MTCO2, MTCO4), peroxisome proliferator activated receptor gamma coactivator 1α (PGC-1α); lysosomes: early endosome antigen 1, lysosome activated membrane protein 1; and cell signaling: extracellular signal regulated kinase (ERK1/2). Lysotracker and Mitotracker were used to monitor mitochondria morphology and organelle co-localization. Compared with controls, untreated COPD ASMCs showed lower collagen type-I and α-SMA expressions, but increased fibronectin levels. CSE further downregulated collagen type-I and α-SMA expression, but upregulated fibronectin. CSE decreased PGC-1α, MTCO2, and MTCO4, but increased beclin-1, p62, and LC3. CSE upregulated mitophagy and lysosomes activity via ERK1/2 phosphorylation. In vitro, cigarette smoke induced the deterioration of ASMCs, which might explain the tissue loss and structural remodeling in COPD bronchi. The results suggest that preventing exceeded mitophagy in ASMCs might present a novel therapeutic target for COPD.
In clinical studies, OM-85 Broncho-Vaxom®, a bacterial lysate, reduced viral respiratory tract infection. Infection of epithelial cells by SARS-CoV-2 depends on the interaction of its spike-protein (S-protein) with host cell membrane proteins. In this study, we investigated the effect of OM-85 on the expression of S-protein binding proteins by human bronchial epithelial cells. Human bronchial epithelial cells were treated with OM-85 over 5 days. The expression of SARS-CoV-2 receptor angiotensin converting enzyme 2 (ACE2), transmembrane protease serine subtype 2 (TMPRSS2), dipeptidyl peptidase-4 (DPP4), and a disintegrin and metalloprotease 17 (ADAM17) were determined by Western blotting and quantitative RT-PCR. Soluble (s)ACE2, heparan sulfate, heparanase, and hyaluronic acid were assessed by ELISA. OM-85 significantly reduced the expression of ACE2 (p < 0.001), TMPRSS2 (p < 0.001), DPP4 (p < 0.005), and cellular heparan sulfate (p < 0.01), while ADAM17 (p < 0.02) expression was significantly upregulated. Furthermore, OM-85 increased the level of sACE2 (p < 0.05), hyaluronic acid (p < 0.002), and hyaluronan synthase 1 (p < 0.01). Consequently, the infection by a SARS-CoV-2 spike protein pseudo-typed lentivirus was reduced in cells pretreated with OM-85. All effects of OM-85 were concentration- and time-dependent. The results suggest that OM-85 might reduce the binding of SARS-CoV-2 S-protein to epithelial cells by modification of host cell membrane proteins and specific glycosaminoglycans. Thus, OM-85 might be considered as an add-on for COVID-19 therapy.
Heat shock protein 70 (HSP70) regulates the ligand binding of the glucocorticoid receptor (GR). In asthma patients, heat treatment increased both the GR expression and secretion of extracellular HSP70 (eHSP70) by bronchial epithelial cells (EC). The objective of this study was to assess the effects of eHSP70 on GR expression and the GR-dependent regulation of immune response in human bronchial ECs. Cells were treated with either eHSP70 or transfected with an expression vector for intracellular HSP70 (iHSP70). Ribonucleic acid (RNA) and protein levels were detected by reverse transcriptase-polymerase chain reaction (RT-PCR), Western blotting, and immunofluorescence. Interleukin (IL-6 and IL-8) secretion was determined by enzyme linked immunosorbent assay (ELISA). The overexpression of iHSP70 decreased, while eHSP70 increased GR expression. In addition, eHSP70 increased the expression of the GR target dual-specificity phosphatase 1 (DUSP-1). In doing so, eHSP70 reduced the tumor growth factor (TGF)-β1-dependent activation of extracellular signal-regulated kinase (Erk)-1/2 and cyclic AMP response element binding protein (CREB) and the secretion of IL-6 and IL-8. Blocking the GR or Toll-like receptor 4 (TLR4) counteracted all eHSP70-induced effects. This study demonstrates a novel anti-inflammatory effect of eHSP70 by the signaling cascade of TLR4-GR-DUSP1, which inhibits TGF-β1-activated pro-inflammatory ERK1/2-CREB signaling and cytokine secretion. The findings suggest that eHSP70 might present a novel non-steroidal therapeutic strategy to control airway inflammation in asthma.
Airway epithelium repair after infection consists of wound repair, re-synthesis of the extracellular matrix (ECM), and tight junction proteins. In humans, EPs® 7630 obtained from Pelargonium sidoides roots reduces the severity and duration of acute respiratory tract infections. The effect of EPs® 7630 on tissue repair of rhinovirus-16 (RV-16) infected and control human airway epithelial cells was assessed for: (i) epithelial cell proliferation by manual cell counts, (ii) epithelial wound repair by “scratch assay”, (iii) ECM composition by Western-blotting and cell-based ELISA, and (iv) epithelial tight junction proteins by Western-blotting. EPs® 7630 stimulated cell proliferation through cAMP, CREB, and p38 MAPK. EPs® 7630 significantly improved wound repair. Pro-inflammatory collagen type-I expression was reduced by EPs® 7630, while fibronectin was increased. Virus-binding tight junction proteins desmoglein2, desmocollin2, ZO-1, claudin1, and claudin4 were downregulated by EPs® 7630. The RV16-induced shift of the ECM towards the pro-inflammatory type was prevented by EPs® 7630. Most of the effects of EPs® 7630 on tissue repair and regeneration were sensitive to inhibition of cAMP-induced signaling. The data suggest that EPs® 7630-dependent modification of epithelial cell metabolism and function might underlie the faster recovery time from viral infections, as reported by others in clinical studies.
Background: Bronchial thermoplasty (BT) is applied to patients with severe uncontrolled asthma. BT reduced airway wall remodeling and increased quality of life and many patients could reduce the steroiduse. BT modified the expression of heat shock proteins which keep the glucocorticoid receptor (GR) in its ligand binding formation. Aims: To examine the expression of the GR in tissue sections of the bronchus before and after BT. Methods: Endobronchial biopsies (n=450) were collected from 30 patients with severe uncontrolled asthma before BT and after one month each of three sequential BT applications. The GR expression was determined in bronchial tissue sections by immunohistochemistry. Results: In all tissues, the GR was expressed in both epithelial cells (EC) and in subepithelial mesenchymal cells (SMC). In EC, the GR expression was higher than in SMC. Compared to before BT, the GR expression was significantly up-regulated after BT in EC (p=0.018) and in SMC (p=0.033). Furthermore, after BT the GR signal was significantly increased in the nucleus compared to tissue section obtained before BT (p=0.036). Conclusion: BT lastingly increased the expression of the GR in EC and SMC. And it was shifted the GR into the nucleus. Epithelial cells require steroids for their recovery from stress and for their differentiation, thus the lasting increased GR expression and its accumulation in the nucleus might help them to repair tissue damage during asthma attacks. In SMC steroids supress proliferation and inflammation.The increased GR expression in SMC might therefore help to reduce airway remodelling. The presented data may explain the reduced requirement of steroids for asthma therapy after BT.
Background: Bronchial thermoplasty is applied to patients with severe asthma. Besides reducing airway wall remodeling and increasing quality of life, it was reported that the use of steroid could be reduced. We reported earlier that glucocorticoid receptor (GR) regulating heat shock proteins were affected by bronchial thermoplasty. Aim:In vitro assessment regarding the effect of heat on the expression of the GR by airway smooth muscle cells (ASMC) and epithelial cells (EC). Methods: Immortalized human bronchial epithelium (BEAS-2B), human primary EC (n=14) and ASMC (n=27) were treated with increasing temperatures (37, 45, 55, 65ºC) for 10 seconds. The cells were incubated for 24h and 48h, in the presence and absence of steroids (10-8M). GR expression was determined by qPCR, Western-blotting and immunohistochemistry. Results: ASMC were significantly more sensitive to heat than EC. ASMC and BEAS-2B cells showed signs of apoptosis at temperatures above 50ºC, while primary EC showed no sign of cell death. Exposure to 65ºC reduced the expression of the GR in ASMC without any significant difference between controls, asthma, and COPD patients at 24h or 48h. In contrast, increasing heat significantly upregulated the expression of the GR in EC, but not in BEAS-2B cells. The cell type specific response of the GR to heat was confirmed on the level of transcription, and protein expression. Conclusion: Bronchial thermoplasty or heat application modifies the expression of the GR in a cell type specific manner. This may explain the reduced requirement of steroids for asthma therapy after bronchial thermoplasty.